TrialLeukemia2022

Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.

Ciara L Freeman et al.PubMed ↗Publisher ↗

No numbers read from the abstract.